ISSUE 1244
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Three new combination oral contraceptives (COCs) with shortened hormone-free intervals, Seasonique, Loestrin 24 Fe and Yaz, have recently been approved by the FDA. All 3 are derivatives of older products.
RATIONALE — Theoretically, shortened hormone-free intervals would reduce hormone withdrawal symptoms, particularly withdrawal bleeding, and decrease the risk of ovulation and pregnancy. One study found that contraceptive regimens with shorter hormone-free intervals suppressed ovarian hormone production more effectively than those with the traditional 7-day interval.1
SEASONIQUE — As with its predecessor Seasonale,2 Seasonique has a 91-day cycle. With both products, active tablets are taken for 84 consecutive days, decreasing the number of withdrawal bleeds annually from 13 with standard 28-day-cycle
... moreWould you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1244a
Electronic, downloadable article - $45